AlphAIAlphAI — Financial news for AI agents
fool.comSEP 243 min read$BMY

Bristol Myers Squibb and Johnson & Johnson Both Face Challenges Ahead: Which Healthcare Stock Looks More Resilient Now?

Bristol Myers Squibb (BMY) and Johnson & Johnson (JNJ) are compared. BMY reported $48.2B revenue, $7.1B net income in FY 2025, with a 2.6x debt-to-equity ratio. JNJ reported $94.2B revenue, $26.8B net income, with a 0.6x debt-to-equity ratio. Both face regulatory and litigation risks, but JNJ's diversified business and stronger balance sheet may offer more resilience.

Original reporting
fool.com
Published Sep 24, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 24, 2026, 12:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Bristol Myers Squibb and Johnson & Johnson Both Face Challenges Ahead: Which Healthcare Stock Looks More Resilient Now? — source image
Source · fool.com
Decision brief

The 30-second read

$BMYNeutralLow
01

Why it matters

The article offers no new quantitative data; it merely restates publicly filed annual report numbers and provides qualitative commentary.

02

Market read

The article is a low‑value comparative analysis without fresh information, offering limited trading relevance.

03

What to watch

Potential impact of upcoming FDA decisions on pipeline drugs and the execution risk of JNJ's orthopedics spin‑off.

Relevance 4/10Novelty 2/10Timing: post‑FY2025 earnings recap

Background

The piece is a side‑by‑side comparison of two major healthcare companies, using their FY 2025 results and risk narratives.

Company-level read

Ticker impact

$BMYNeutralMedium confidence
Context

The article recaps Bristol Myers Squibb's FY 2025 financials and risks, but provides no new data beyond prior filings.

Expected impact

Sideways to slight downside if investors focus on litigation risk.

Evidence & confidence

Numbers are already public; only opinion adds marginal perspective.

$JNJNeutralMedium confidence
Context

The article summarizes Johnson & Johnson's FY 2025 results and upcoming orthopedics spin‑off, without new disclosures.

Expected impact

Likely flat to modestly positive if investors favor diversification narrative.

Evidence & confidence

All figures were released in the company's 2025 annual report.

Market effects

Sector

Reinforces the ongoing debate over biotech vs diversified health‑care exposure.

Regional

Limited; both firms are large U.S. multinationals with global footprints.

Global

Low; no new macro or sector‑wide data introduced.

Counterpoint

What could challenge this read

Investors might view the litigation and patent‑cliff risks at BMY as a buying opportunity if the market over‑penalizes them.

Key entities

  • Company
    Bristol Myers Squibb

    US‑listed biopharma (ticker BMY) with FY 2025 revenue $48.2B.

  • Company
    Johnson & Johnson

    US‑listed diversified health conglomerate (ticker JNJ) with FY 2025 revenue $94.2B.

Read at source← All news

Related articles

SEP 25
$JNJHighAI 8/10

Johnson & Johnson Reports TREMFYA STAR Trial Results

Johnson & Johnson (JNJ) reported positive Phase 4 STAR trial results for TREMFYA in treating axial psoriatic arthritis. The drug met primary and major secondary endpoints, showing improvements in disease activity, axial symptoms, and MRI-measured inflammation at Week 24. The safety profile was consistent with previous findings. Detailed results will be presented at a future scientific congress.

grafa.com2 min
SEP 25
$JNJLow

Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma

Johnson & Johnson (JNJ) reported that 50% of patients in a Phase 2 study of CARVYKTI® (ciltacabtagene autoleucel) for early-line relapsed/refractory multiple myeloma achieved five-year treatment-free remission. The study, presented at the International Myeloma Society Annual Meeting, showed a 69.2% five-year overall survival rate and 60.5-month median progression-free survival. The company suggests earlier treatment may increase long-term remission and disease control.

prnewswire.com2 min
SEP 25
$JNJMedAI 8/10

Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study

Johnson & Johnson (JNJ) reported positive results from the Phase 4 STAR study of TREMFYA (guselkumab) in patients with axial psoriatic arthritis (PsA). The drug met primary and major secondary endpoints, showing improvement in spinal pain, stiffness, and MRI-confirmed inflammation. JNJ aims to position TREMFYA as a first-line treatment for axial PsA, an area with significant unmet needs. Detailed results will be presented at an upcoming scientific congress.

prnewswire.com2 min
SEP 25
$JNJMedAI 8/10

Half of patients in a J&J study were alive without worsening myeloma five years after one infusion

Johnson & Johnson (JNJ) reported that 50% of patients in a Phase 2 study of CARVYKTI® for multiple myeloma were alive and progression-free five years after a single infusion. The study, presented at the International Myeloma Society Annual Meeting, showed a 69.2% overall survival rate and 60.5-month median progression-free survival. CARVYKTI is approved in 17 markets and has treated over 13,000 patients globally, according to the company.

stocktitan.net2 min